A Phase 2 interventional study of Roflumilast and Pioglitazone in Nonalcoholic Steatohapatitis, sponsored by AstraZeneca. Terminated at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.
This proof of concept study will evaluate the effect of roflumilast and pioglitazone on transaminase levels and liver fat content.
Takeda has chosen not to continue this Study, however, randomized subjects were allowed to complete the study per protocol.
The decision to terminate the study is not related to any safety concerns with either of the study medications.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast dose and pioglitazone dose, orally for up to 4 months
Drug: Roflumilast · Drug: Pioglitazone
Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
Drug: Roflumilast · Drug: Placebo
Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
Drug: Pioglitazone · Drug: Placebo
Roflumilast dose
Also known as: Daxas, Daliresp
Pioglitazone dose
Also known as: Actos
Pioglitazone placebo-matching dose
Roflumilast placebo-matching dose
Amount of Serum Alanine Transaminase (ALT) at Baseline
Time frame: Baseline
Percent Change From Baseline in Serum ALT at Month 4
The percent change between the serum ALT value collected at Month 4 or final visit relative to baseline.
Time frame: Month 4
Amount of Serum Aspartate Transaminase (AST) at Baseline
Time frame: Baseline
Percent Change From Baseline in Serum AST at Month 4
The percent change between the serum AST value collected at Month 4 or final visit relative to baseline.
Time frame: Month 4
Liver Fat Content at Baseline
Liver fat content was quantitatively measured by evaluating the percentage of proton density fat fraction (PDFF) from an abdominal magnetic resonance imaging (MRI). On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.
Time frame: Baseline
Change From Baseline in Liver Fat Content at Month 4
Liver fat content was quantitatively measured by evaluating the percentage of PDFF from an abdominal MRI. On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.
Time frame: Baseline and Month 4
Participants took part at 11 sites in the United States from 26 April 2013 to 30 September 2014.
| Milestone | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Started | 7 | 7 | 6 |
| Completed | 4 | 3 | 3 |
| Not completed | 3 | 4 | 3 |
| Withdrew: Adverse event | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Study termination | 1 | 2 | 0 |
| international units per liter (IU/L) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Amount of Serum Alanine Transaminase (ALT) at Baseline | 101.7 ± 56.98 | 83.4 ± 31.63 | 118.8 ± 36.76 |
The percent change between the serum ALT value collected at Month 4 or final visit relative to baseline.
| percent change | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Percent Change From Baseline in Serum ALT at Month 4 | -53.89 ± 23.362 | -56.22 ± 6.014 | -28.86 ± 53.298 |
| IU/L | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Amount of Serum Aspartate Transaminase (AST) at Baseline | 64.0 ± 43.49 | 44.9 ± 15.25 | 88.3 ± 73.06 |
The percent change between the serum AST value collected at Month 4 or final visit relative to baseline.
| percent change | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Percent Change From Baseline in Serum AST at Month 4 | -41.31 ± 36.087 | -43.20 ± 7.339 | -17.56 ± 45.458 |
Liver fat content was quantitatively measured by evaluating the percentage of proton density fat fraction (PDFF) from an abdominal magnetic resonance imaging (MRI). On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.
| percentage of PDFF | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Caudate; (n= 6, 7, 6) | 22.233 ± 8.2750 | 19.107 ± 7.7990 | 20.117 ± 9.8492 |
| Left superolateral; (n= 6, 6, 6) | 19.485 ± 8.8080 | 17.813 ± 7.4410 | 17.278 ± 7.2225 |
| Left inferolateral; (n= 6, 7, 6) | 22.385 ± 8.9894 | 19.747 ± 7.8306 | 19.153 ± 10.5909 |
| Left superomedial: (n= 6, 7, 6) | 22.115 ± 9.7126 | 20.426 ± 7.9170 | 20.100 ± 9.8688 |
| Left inferomedial: (n= 6, 6, 6) | 21.553 ± 9.5912 | 18.977 ± 8.6970 | 21.530 ± 9.5193 |
| Right anteroinferior: (n= 6, 7, 6) | 22.478 ± 9.0548 | 19.994 ± 9.0103 | 20.742 ± 8.7829 |
| Right posteroinferior: (n= 6, 7, 6) | 23.710 ± 8.6478 | 18.804 ± 6.6882 | 20.070 ± 9.9727 |
| Right posterosuperior: (n= 6, 7, 6) | 23.282 ± 9.5984 | 18.870 ± 7.5764 | 19.943 ± 8.9666 |
| Right anterosuperior: (n=6, 7, 6) | 23.630 ± 8.7454 | 19.786 ± 8.5929 | 21.527 ± 9.6648 |
Liver fat content was quantitatively measured by evaluating the percentage of PDFF from an abdominal MRI. On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.
| percent change in PDFF | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Caudate; (n= 3, 3, 3) | -18.787 ± 11.5646 | -11.590 ± 5.5674 | -10.287 ± 8.8098 |
| Left superolateral; (n= 6, 6, 6) | -15.170 ± 13.7442 | -10.287 ± 1.9695 | -8.067 ± 7.6318 |
| Left inferolateral; (n= 3, 3, 3) | -14.290 ± 13.1654 | -10.077 ± 2.9030 | -8.773 ± 7.0821 |
| Left superomedial: (n= 3, 3, 3) | -14.687 ± 13.6909 | -11.177 ± 3.9429 | -9.217 ± 8.7999 |
| Left inferomedial: (n= 3, 3, 3) | -14.107 ± 15.2957 | -10.977 ± 5.0052 | -9.417 ± 8.9360 |
| Right anteroinferior: (n= 3, 3, 3) | -13.990 ± 13.1266 | -10.260 ± 6.9972 | -7.693 ± 9.7985 |
| Right posteroinferior: (n=3, 3, 3) | -18.073 ± 13.1470 | -9.250 ± 1.6808 | -8.790 ± 10.2188 |
| Right posterosuperior: (n=3, 3, 3) | -17.717 ± 13.0691 | -9.797 ± 4.4053 | -8.113 ± 10.4166 |
| Right anterosuperior: (n=3, 3, 3) | -16.127 ± 13.9820 | -9.803 ± 3.3661 | -8.647 ± 10.1658 |
Collected over Treatment-emergent AEs will be defined as any AEs, regardless of relationship to study drug, that occur or worsen after the first dose of double-blinded study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast + Pioglitazone | — | 0/7 (0%) | 5/7 (71.4%) |
| Roflumilast Only | — | 0/7 (0%) | 4/7 (57.1%) |
| Pioglitazone Only | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only |
|---|---|---|---|
| Liver function test abnormalInvestigations | 0/7 | 0/7 | 2/6 |
| HeadacheNervous system disorders | 1/7 | 2/7 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/7 | 1/7 | 1/6 |
| NauseaGastrointestinal disorders | 1/7 | 2/7 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/7 | 0/7 | 0/6 |
| EructationGastrointestinal disorders | 0/7 | 0/7 | 1/6 |
| ChillsGeneral disorders | 0/7 | 0/7 | 1/6 |
| FatigueGeneral disorders | 0/7 | 0/7 | 1/6 |
| PyrexiaGeneral disorders | 0/7 | 0/7 | 1/6 |
| InfluenzaInfections and infestations | 1/7 | 1/7 | 1/6 |
The randomized set included all participants who were randomized.
| Age, Continuous(years) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Mean | 45.4 ± 9.64 | 43.9 ± 14.77 | 42.5 ± 8.67 | 44.0 ± 10.93 |
| Age, Customized(participants) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| 18 - 39 years | 3 | 2 | 3 | 8 |
| 40 - 59 years | 4 | 4 | 3 | 11 |
| 60 - 80 years | 0 | 1 | 0 | 1 |
| Gender(Participants) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Female | 5 | 2 | 2 | 9 |
| Male | 2 | 5 | 4 | 11 |
| Race/Ethnicity, Customized(participants) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 1 | 4 |
| Non-Hispanic or Latino | 7 | 4 | 5 | 16 |
| Race/Ethnicity, Customized(participants) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Asian | 0 | 2 | 0 | 2 |
| White | 7 | 4 | 6 | 17 |
| Multiracial | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| United States | 7 | 7 | 6 | 20 |
| Height(centimeter (cm)) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Mean | 165.6 ± 15.13 | 168.7 ± 8.62 | 174.3 ± 7.50 | 169.3 ± 11.13 |
| Weight(kilogram (kg)) | Roflumilast + Pioglitazone | Roflumilast Only | Pioglitazone Only | Total |
|---|---|---|---|---|
| Mean | 102.19 ± 21.041 | 92.06 ± 20.784 | 110.15 ± 15.456 | 101.03 ± 19.887 |
3 further baseline measures are reported on the registry.
The record gives a start of Jun 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Roflumilast · Pioglitazone